Encouraging results from a first-in-human Phase 1 clinical trial of IAVI’s Lassa vaccine candidate published in New England Journal of Medicine
7 Mins read
One dose elicits robust and long-lasting immune responses in healthy adults in the U.S. and Liberia Key takeaways: NEW YORK, NY –…

